By VFC’s Stock House
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) ran to over seven dollars last month on increasing volume as the company’s billion dollar potential took shape and numerous analysts jumped on board with encouraging write-ups and bold price predictions.
Synergy also received a boost when its chief competitor, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) received a setback at the FDA that allows SGYP an extra three months to play catch up in the race to commercialization for each company’s respective product candidate, both of which target the same indication. Synergy’s product Plecanatide, however, has a much more favorable side effect profile, making the Ironwood setback that much more of a key factor when discussing future market potential. Read More
To discuss this article or any stock, please visit The Playground Discussion Forum!















